Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs SpaceX (SPCX) Price & Performance

Charles River Laboratories Intl. IncTrade
SpaceXTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs SpaceX — how do they compare? Charles River Laboratories Intl. Inc trades at $228.88 (market cap $11.14B), while SpaceX trades at $135.64 (market cap $1.79T). The key difference: SpaceX is far larger — about 160.7× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.

CRLSPCX
Market Cap
$11.14B$1.79T
Sector
HealthTechnology
52-Week High
$233.60$202.09
52-Week Low
$145.57$135.00
Enterprise Value
$14.00B$1.81T

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

SpaceX

SpaceX (SPCX) trades at $139.14, down 4.33% with bearish technical signals despite analyst optimism. The stock shows weak fundamentals with negative profitability (-45% net margin) and extreme valuations (P/S 92.17, EV/EBITDA 957.25). Recent Q1 2026 earnings missed expectations, though inclusion in the Nasdaq-100 provides institutional support. Cash flow remains positive primarily from financing activities.

Long-term growth potential in space economy contrasts with current overvaluation and execution risks. Analyst consensus remains bullish with $239.23 price target, but investors face volatility from high valuations and geopolitical tensions. The stock presents high-risk speculation on future space dominance rather than current fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About SpaceX

SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.

Read more on SPCX